Skip to content

Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC Patients

The Impact of Pretreatment Lymphocyte to Monocyte Ratio on Clinical Outcome for Patient With HCC

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03869151
Enrollment
1
Registered
2019-03-11
Start date
2019-04-05
Completion date
2020-03-31
Last updated
2019-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

To assess the prognostic role of pretreatment LMR in hepatocellular carcinoma(HCC).

Detailed description

The exact molecular mechanisms responsible for the prognostic impact of lymphocyte monocyte ratio in Heatocellular carcinoma are unclear.It has been suggested that cross-talk between the inflammatory response and tumor progression play a critical role in the initiation and progression of Heatocellular carcinoma. In the tumor microenvironment, inflammatory infiltrates have a large influence on the biological behavior of Heatocellular carcinoma. Tumor-infiltrating lymphocytes, as representative component of the immune microenvironment ,are implicated in several stages of Heatocellular carcinoma progression, and Tumor-infiltrating lymphocytes phenotypes may be a predictor for favorable prognosis. Conversely, low lymphocyte counts might result in an insufficient immunological reaction, which lead to inferior survival in multiple cancers. Monocytes infiltrating tumor tissue are also involved in Heatocellular carcinoma development and progression. Activated monocytes in Heatocellular carcinoma micro environments can trigger and polarize T-cell responses and facilitate inflammation-induced tumor development. Tumor-associated macrophages are derived from circulating monocytes. Tumor-associated macrophages can accelerate Heatocellular carcinoma cell proliferation,tumor-associated angiogenesis, and metastasis. Several studies showed that high infiltration of Tumor-associated macrophages predicted decreased survival in various cancers.

Interventions

DIAGNOSTIC_TESTCBC

lymphocyte and monocyte count

Sponsors

Amany Aboalenen Amin
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Patients with child A Hepatocellular carcinoma.

Exclusion criteria

* Patients with child C Hepatocellular carcinoma. * Patients with heart failure

Design outcomes

Primary

MeasureTime frameDescription
increased over all survival1 yearElevated pretreatment lymphocyte monocyte ratio may be a favorable prognostic factor for clinical outcomes in patients with hepatocellular carcinoma.

Contacts

Primary Contactamany Amin, master
dr.ma777moud@gmail.com+201093930042

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026